ZenzeTech is currently looking for investors
We are closing in November ’23 – Contact us to hear more about the opportunity to invest in ZenzeTech
1 min pitch
Instead of finding the right medication taking 10 years, we want to do it within 1 week
Meet ZenzeTech’s co-founder and CEO, Christian, delivering a one-minute pitch about the problem and solution
Principles of business
Gaining insights from our investors
Discover what they have to say about ZenzeTech and why they invested
Life Science Investor
“Two key elements came into play when I invested in ZenzeTech – team and technology trends. I was impressed by the team behind ZenzeTech, they appeared trustworthy, calm, and composed with a good vision. Magdalena and Christian complement each other well; both being calm and Magdalena with a focus on making things work and Christian being more outgoing, it makes sense. It was good for me, with my regulatory background, to see that ZenzeTech was validated by Voisin Consulting Life Science, which substantiated the team further. Data as digital endpoints for therapeutic use is a big trend, and now with ZenzeTech we can see data used for treatment purposes. Using insoles for Parkinson’s Disease is a very interesting approach with a big potential.”
Jesper has 40 years of experience within Life Science, primarily in leadership positions. For 25 years he worked with regulatory affairs, e.g. as Global Head of Regulatory Affairs at LEO Pharma and Vice President of Regulatory Affairs at Novo Nordisk. After a career in corporate, Jesper has devoted his time working with Life Science startups – Pharma, Biotech, Medtech and Healthtech – as a mentor, board member and investor.
DeepTech and Impact Investor
“It is very important for me to trust the team. Christian and Magdalena possess a high degree of credibility, are transparent and honest which creates trust while they have the competencies to succeed. They are good at drawing experienced people in and listening to them. Also, the timing is important. I prioritize that the product addresses a real problem – which means that there is a product market fit. I think there is. ZenzeTech has a good idea with a combination of hardware in an insole and data driven approach to help neurologists to assess the medical treatment.”
Helle has 35 years of experience from Haldor Topsøe where she worked with various new projects from developing new products and markets to setting up production. Through these experiences, Helle knows what it takes to create successful projects and businesses. Since 2020 she has been a full-time mentor and angel investor. Through her dedication in the startup environment, she won the Investor Rising Star of the Year 2023 award in Denmark. Her portfolio consists of DeepTech start-ups which supports the green transformation or that have a positive impact on human lives.
Thomas R. Lund
“The idea of an insole providing data is good, it is a simple solution for the patient and neurologist to understand. ZenzeTech is addressing a big problem and therefor a big market. It is also a relatively short and simple path to market with the users and buyers clearly defined. The product solution is easy to distribute compared to other larger or sensitive medical devices and it is scalable to other markets. Furthermore, the team has demonstrated to be on top of regulatory affairs early on.”
After his career at Coloplast he became CEO of Advalight, a medical device startup, which he led from a university project to pilot-production with FDA 510k and ISO 13485 approval including a US subsidiary. Since 2010 he has invested in MedTech startups including ZenzeTech in 2022.